Vol. 3 No. 3 (2009) | Hematology Meeting Reports

Current Issue

Vol. 3 No. 3 (2009)

12 June 2009

View this Issue

Vol. 3 No. 3 (2009)

Published: 12 June 2009

7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009

Proceedings

7th Meeting New Insight in Hematology

Teodoro Chisesi

https://doi.org/10.4081/hmr.v3i3.590

286

PDF: 378
- PDF

Abstracts

Molecular targeted therapies for indolent lymphomas: where are we?

G Saglio, G Parvis, M Bosa

https://doi.org/10.4081/hmr.v3i3.554

288

PDF: 304
- PDF
The indolent extranodal lymphomas: What is the role of radiation therapy?

RT Hoppe

https://doi.org/10.4081/hmr.v3i3.555

291

PDF: 785
- PDF
Alterations of microenvironment in multiple myeloma patients: interactions between myeloma cells and osteoprogenitor cells

N Giuliani, V Rizzoli

https://doi.org/10.4081/hmr.v3i3.556

294

PDF: 335
- PDF
New treatment options for elderly myeloma patients: the Italian experience

A Palumbo, M Genuardi, S Bringhen

https://doi.org/10.4081/hmr.v3i3.557

279

PDF: 351
- PDF
The road to cure in multiple myeloma: incorporation of novel agents into autologous stem cell transplantation

M Cavo, E Zamagni, P Tacchetti, A Brioli, C Pallotti, L Pantani, M Ceccolini, A Petrucci, N Testoni, C Terragna, G Marzocchi, S Durante, P Tosi, M Baccarani

https://doi.org/10.4081/hmr.v3i3.558

323

PDF: 184
- PDF
The role of thalidomide as maintenance after autologous stem-cell transplantation in multiple myeloma

A Maiolino, V Tietsche de Moraes Hungria, M Nucci, C De Souza

https://doi.org/10.4081/hmr.v3i3.559

259

PDF: 257
- PDF
The role of maintenance treatment in myeloma

M Attal

https://doi.org/10.4081/hmr.v3i3.560

239

PDF: 254
- PDF
Have maintenance rituximab and RIC allograft blown away the need for autografts in follicular lymphoma?

AH Goldstone

https://doi.org/10.4081/hmr.v3i3.561

243

PDF: 178
- PDF
Reduced-intensity conditioning for allograft after cytoreductive autograft in relapsed/ resistant Hodgkin’s lymphoma

AM Carella, E Todisco, A Congiu, L Castagna, G Pica, G Beltrami, S Nati, R Vimercati, E Rossi, M Spriano, G Catania, A Santoro

https://doi.org/10.4081/hmr.v3i3.563

313

PDF: 186
- PDF
Long-term results of reduced-intensity conditioning followed by allogeneic transplantation in relapsed lymphomas

P Corradini, A Dodero, L Farina, R Fanin, F Patriarca, R Miceli, P Matteucci, R Scimè, F Narni, S Dalto, C Carniti, A Bacigalupo, F Bonifazi, A Olivieri, C Tarella

https://doi.org/10.4081/hmr.v3i3.564

369

PDF: 230
- PDF
Brazilian experience using high dose sequential followed by autologous hematopoietic stem cell transplantation for malignant lymphomas

BKL Duarte, AC Vigorito, FJP Aranha, R Baldissera, ECM Miranda, IL Lorand-Metze, KB Pagnano, CA De Souza

https://doi.org/10.4081/hmr.v3i3.566

274

PDF: 229
- PDF
Large cell non Hodgkin’s lymphoma: what is new in the WHO classification?

PP Piccaluga, F Bacci, E Sabattini, M Rossi, A Gazzola, MR Sapienza, C Mannu, S Righi, C Bertuzzi, C Agostinelli, MT Sista, C Laterza, S Parisi, SA Pileri

https://doi.org/10.4081/hmr.v3i3.567

290

PDF: 412
- PDF
High-dose CHOP in the rituximab era: still a place?

B Coiffier

https://doi.org/10.4081/hmr.v3i3.568

279

PDF: 291
- PDF
Radiotherapy in the rituximab era: still a place?

M Pfreundschuh

https://doi.org/10.4081/hmr.v3i3.569

333

PDF: 195
- PDF
S.J. Horning Biomarkers in diffuse large B-cell lymphoma

SJ Horning

https://doi.org/10.4081/hmr.v3i3.570

255

PDF: 555
- PDF
High dose chemotherapy and autologous transplantation in anti-CD20 antibodies era: still a place?

U Vitolo, A Chiappella, B Botto

https://doi.org/10.4081/hmr.v3i3.571

233

PDF: 305
- PDF
Recent advances in the pathology of idiopathic thrombocytopenic purpura

L Catani

https://doi.org/10.4081/hmr.v3i3.572

300

PDF: 1006
- PDF
Idiopathic thrombocytopenic purpura in adults: the treatment paradigm

F Zaja, R Fanin

https://doi.org/10.4081/hmr.v3i3.573

249

PDF: 635
- PDF
Thrombopoietin receptor agonists in the treatment of chronic immune thrombocytopenic purpura

A Cuker, EY Chiang, DB Cines

https://doi.org/10.4081/hmr.v3i3.574

354

PDF: 970
- PDF
Are we getting closer to understanding the pathogenesis of chronic lymphocytic leukemia?

F Caligaris-Cappio, C Scielzo, S Bertilaccio, M Muzio, P Ghia

https://doi.org/10.4081/hmr.v3i3.575

321

PDF: 502
- PDF
The continuing search for the cell of origin of chronic lymphocytic leukemia

M Ferrarini

https://doi.org/10.4081/hmr.v3i3.576

233

PDF: 719
- PDF
Molecular cytogenetic lesions in chronic lymphocytic leukemia

A Cuneo, F Cavazzini, M Ciccone, M Dabusti, F Cibien, G Daghia, O Sofritti, GM Viglione, GM Rigolin

https://doi.org/10.4081/hmr.v3i3.577

276

PDF: 900
- PDF
What is gene profiling contributing to the characterization of chronic lymphocytic leukemia

R Foà, A Guarini, I Del Giudice, S Tavolaro, S Chiaretti

https://doi.org/10.4081/hmr.v3i3.578

242

PDF: 192
- PDF
The impact of diagnosis on the therapeutic management of chronic lymphocytic leukemia

V Liso, R Rizzi

https://doi.org/10.4081/hmr.v3i3.579

268

PDF: 293
- PDF
How close are we to curing chronic lymphocytic leukemia?

MJ Keating

https://doi.org/10.4081/hmr.v3i3.580

228

PDF: 276
- PDF
Cyclophosphamide in chronic lymphocytic leukemia first line: final results of Chronic Lymphocytic Leukemia 8 Study

M Gobbi

https://doi.org/10.4081/hmr.v3i3.581

5654

PDF: 871
- PDF
Lenalidomide: an emerging option in chronic lymphocytic leukemia

A Ferrajoli, SM O’Brien, SM O’Brien, S Faderl1, S Faderl1, WG Wierda, WG Wierda, JM Reuben, JM Reuben, MJ Keating, MJ Keating

https://doi.org/10.4081/hmr.v3i3.582

254

PDF: 246
- PDF
Ofatumumab: a second generation anti-CD20 monoclonal antibody in chronic lymphocytic leukemia

M Montillo

https://doi.org/10.4081/hmr.v3i3.583

274

PDF: 425
- PDF
Hydroxyurea: the comparator in studies with new anti-JAK2 inhibitors

G Finazzi, T Barbui

https://doi.org/10.4081/hmr.v3i3.584

334

PDF: 676
- PDF
New biologic and therapeutic insights in Hodgkin’s lymphoma

GP Canellos, W Rosenberg

https://doi.org/10.4081/hmr.v3i3.585

246

PDF: 307
- PDF
Treatment approaches in early stage Hodgkin’s lymphoma

DJ Straus

https://doi.org/10.4081/hmr.v3i3.586

230

PDF: 582
- PDF
Advanced Hodgkin’s lymphoma: doxorubicin, bleomycin, vinblastine, dacarbazine and beyond

V Diehl

https://doi.org/10.4081/hmr.v3i3.587

297

PDF: 305
- PDF
Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone outside German Hodgkin Study Group: the Italian experience

S Luminari, M Federico, A Montanini, E Iannitto, G Polimeno, PG Gobbi

https://doi.org/10.4081/hmr.v3i3.588

291

PDF: 585
- PDF
Treatment of refractory Hodgkin’s lymphoma: a puzzle to merge

A Santoro, A Anastasia, R Mazza

https://doi.org/10.4081/hmr.v3i3.589

204

PDF: 332
- PDF
Blastic plasmacytoid dendritic cell neoplasm

F Facchetti, M Ungari, D Marocolo, S Lonardi, W Vermi

https://doi.org/10.4081/hmr.v3i3.553

4976

PDF: 4357
- PDF

© PAGEPress 2008-2026 • PAGEPress^® is a registered trademark property of PAGEPress srl, Italy • VAT: IT02125780185
This journal is published by PAGEPress® srl (Pavia, Italy), which is the data controller for all personal data processed through this platform. For full details on how your data is collected, used and protected, please read our Privacy Policy.